Trial Profile
An open label, crossover study to evaluate the potential pharmacodynamic interaction between inclacumab and unfractionated heparin in healthy smokers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Feb 2016
Price :
$35
*
At a glance
- Drugs Inclacumab (Primary) ; Heparin
- Indications Coronary artery disease
- Focus Pharmacodynamics; Pharmacokinetics
- 15 Feb 2016 New trial record